Boston Trust Walden Corp Sells 7,805 Shares of CVS Health Corporation $CVS

Boston Trust Walden Corp trimmed its stake in CVS Health Corporation (NYSE:CVS) by 54.2% in the first quarter, Holdings Channel reports. The firm owned 6,608 shares of the pharmacy operator’s stock after selling 7,805 shares during the quarter. Boston Trust Walden Corp’s holdings in CVS Health were worth $475,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Keybank National Association OH raised its stake in shares of CVS Health by 12.4% during the 1st quarter. Keybank National Association OH now owns 96,324 shares of the pharmacy operator’s stock worth $6,918,000 after purchasing an additional 10,596 shares in the last quarter. Heritage Investors Management Corp increased its holdings in CVS Health by 2.6% during the first quarter. Heritage Investors Management Corp now owns 9,031 shares of the pharmacy operator’s stock worth $649,000 after buying an additional 225 shares during the last quarter. Vision Capital Management Inc. raised its position in CVS Health by 2.0% during the first quarter. Vision Capital Management Inc. now owns 48,713 shares of the pharmacy operator’s stock worth $3,499,000 after acquiring an additional 974 shares in the last quarter. Essex Financial Services Inc. raised its position in CVS Health by 6.9% during the first quarter. Essex Financial Services Inc. now owns 21,384 shares of the pharmacy operator’s stock worth $1,536,000 after acquiring an additional 1,389 shares in the last quarter. Finally, Financial Life Planners acquired a new stake in CVS Health in the first quarter valued at $48,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS stock opened at $104.74 on Friday. The company has a market capitalization of $133.64 billion, a price-to-earnings ratio of 46.14, a PEG ratio of 1.03 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The company has a 50-day simple moving average of $94.56 and a 200 day simple moving average of $83.29. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $106.15.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a research note on Thursday, June 11th. Argus lifted their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Royal Bank Of Canada boosted their price target on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, Sanford C. Bernstein upped their price objective on CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.